Strategies for targeting T-cells in allergic diseases and asthma.
T helper (Th) 2 lymphocytes play a crucial role in the initiation, progression and persistence of allergic diseases, including asthma. Drugs that interfere with the activation of T-cells or more selectively Th2-specific signaling molecules and drugs that prevent the selective migration into lung tissue are promising novel strategies for the treatment of allergic asthma. Although the mainstay asthma therapy of inhaled glucocorticoids is rather effective, targeting Th2 cells may be an important alternative in childhood. Regulatory T-cells (Treg cells) have a physiological role in protection of unwanted immune responses to auto-antigens and allergens. Literature data indicate that an imbalance between Th2 and Treg cells may underlie development and disease expression of allergic asthma. Drugs or immunotherapies that stimulate these counter-Treg cells may limit aberrant Th2 responses leading to suppression of symptoms. Furthermore, these types of treatments may offer the perspective of disease modification and long-term relief of symptoms.
Heijink
I H
IH
Laboratory of Allergology and Pulmonary Diseases, Groningen University Medical Center, Groningen University, 9700 RB Groningen, The Netherlands.
Van Oosterhout
A J M
AJ
D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D000242:Cyclic AMP; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use; D007249:Inflammation; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D005938:Glucocorticoids; D007155:Immunologic Factors; D000242:Cyclic AMP